Sitagliptin

Brand Name: Sita-G

Product Fact File:

Sitagliptin is the first antidiabetic agent from the class of dipeptidyl peptidase-4 enzyme
inhibitors. It increases the amount of circulating incretins, which stimulate insulin secretion
and inhibit glucose production. Sitagliptin was approved by the US Food and Drug
Administration (FDA) for use with diet and exercise to improve glycemic control in adult
patients with type 2 diabetes. It can be used alone or in combination with metformin or
a thiazolidinedione (pioglitazone or rosiglitazone) when treatment with either drug alone
provides inadequate glucose control. The usual adult dose is 100 mg once daily. A dose of
25-50 mg once daily is recommended for patients with moderate-to-severe renal
impairment.

In randomized, placebo-controlled trials that lasted for up to 6 months, sitagliptin lowered

glycosylated hemoglobin levels by 0.5-0.8%. In a 52-week clinical trial, sitagliptin was shown
to be noninferior to glipizide as an add-on agent in patients inadequately controlled
on metformin alone. Sitagliptin was well tolerated with the most common side effects being
gastrointestinal complaints (up to 16%), including abdominal pain, nausea and diarrhea;
hypoglycemia and body weight gain occurred at similar rates compared with placebo.
Overall, sitagliptin provides a treatment option for patients with type 2 diabetes as a
monotherapy, or as an adjunct to metformin or a thiazolidinedione when patients achieve
inadequate glycemic control while on either of the agents. It is also an alternative therapy
for those patients who have contraindications or intolerability to other antidiabetic agents.
Approximately 12.4 hours. Other studies have reported a half-life of approximately 11
hours.

Sitagliptin is a prescription drug. It comes as an oral tablet as the brand-name drug Januvia.

It’s not available as a generic drug.

Januvia is the innovator brand by Merck Sharp Dohme in Jan 2014, positioned as 1st Gliptin
in the world, quality and quantity of scientific data is enormous, very good availability, good
results because of +ve feedback from patients, prescribed as add on alongwith other
antidiabetics, Top of the mind recall.

Dosage: Tablet;Oral , Once Daily.

Market Trend:
Diabetes is a chronic metabolic disease that causes high blood sugar due to which body
becomes incapable of producing insulin. According to World Health Organization (WHO),
India had 69.2 million people living with diabetes (8.7%) in 2015. About 90% of the patients
are suffering from Type 2 diabetes. Increasing awareness, increasing number of patients,
untouched rural market, increasing urbanization, developing healthcare infrastructure and
increasing spending on healthcare are driving the market for diabetes in India. India
Diabetes Market is expected to grow at the average CAGR of 6.5% during 2016-2023. India
Diabetes Market is growing rapidly. India Diabetes Market is expected to grow US$ 7441.6
million by 2023 from US$ 4778.7 million in 2016.
Diabetic complications data : Hyperlipidemia(Cholesterol) – 25% patients,
Nephropathy(Kidney Disease) – 25 to 35% patients, Hypertension(Blood Pressure) – 30%
patients, Retinopathy(Eyesight) – almost 80% after 25 years of diabetes.

Current population of india 135crs

Adult population 18-64 is 87 Crs
Health expend